search
Back to results

Transanal Irrigation for the Management of LARS (TAI-LARS)

Primary Purpose

Low Anterior Resection Syndrome, Rectal Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Transanal Irrigation
Sponsored by
Jewish General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Low Anterior Resection Syndrome focused on measuring Transanal irrigations, Quality of Life

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Low anterior resection by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with (or without) creation of a diverting loop ileostomy for the treatment of rectal cancer, advanced adenoma or dysplasia And
  • have had their ileostomy closed (if applicable) And
  • completed treatment at least 6 months ago (including ileostomy closure) And
  • LARS score > 20 points

Exclusion Criteria:

  • Inability to provide informed consent, including fluency in English or French language
  • unable to access the internet,
  • presence of an ostomy,
  • no active or ongoing treatment
  • anastomotic stricture, sinus or any other ongoing anastomotic complications.

Sites / Locations

  • Jewish General HospitalRecruiting
  • McGill University Health Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Transanal Irrigation

Tradition care Control arm

Arm Description

This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm

This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.

Outcomes

Primary Outcome Measures

EORTC-QLQ-C30
Quality of Life change with treatment. Scale scores are calculated by averaging items within scales and transforming average scores linearly. All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems. For more details, are available in the EORTC QLQ-C30 Scoring Manual (Fayers et al., 2001)

Secondary Outcome Measures

LARS Score
Bowel function over the course of treatment. Scores range from 0 to 42 0-20: No LARS 21-29: Minor LARS 30-42: Major LARS
Satisfaction Survey
Satisfaction survey based on LARS Consensus Definition symptoms and consequences
Bowel diaries
Standardize measure of the number of bowel movement per day

Full Information

First Posted
August 10, 2021
Last Updated
February 22, 2023
Sponsor
Jewish General Hospital
Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval
search

1. Study Identification

Unique Protocol Identification Number
NCT05007015
Brief Title
Transanal Irrigation for the Management of LARS
Acronym
TAI-LARS
Official Title
Transanal Irrigation for the Management of Low Anterior Resection Syndrome (LARS): A Multicenter Crossover Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 15, 2022 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jewish General Hospital
Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to evaluate the impact of Transanal irrigation (TAI) on the quality of life and low anterior resection symptoms (LARS) in Canadian rectal cancer survivors living with minor to major LARS. It proposes to teach TAI through a novel online platform and to provide virtual nursing support for the participants. To our knowledge, this is the first North American based and largest randomized control trial on the use of TAI for patients with LARS. This will also be the first study to teach and support patients through the TAI process using a virtual platform. While TAI has been demonstrated to reduce LARS scores and increased QoL in patients with significant LARS, its feasibility and acceptance for Canadian patients remains uncertain. Furthermore despite the existing studies, the rate of TAI seems to be low in North America. The hypothesis is that TAI, taught and supported through an online portal dedicated to LARS patients, will positively impact QoL and improve LARS symptoms. The results of this trial may allow TAI to become part of the standard armamentarium that clinicians offer patients for LARS management, with the presence of online nursing support and guidance to facilitate this practice.
Detailed Description
Low anterior resection syndrome (LARS) is a constellation of bowel symptoms which occur following rectal cancer treatment. These symptoms have a well characterized negative impact on a patient's quality of life (QoL) following sphincter sparing surgery. The treatment of LARS is primarily based on the management of symptoms with conservative measures such as dietary changes and fiber supplements, anti-diarrheal medications and pelvic floor physiotherapy. Despite these measures, patients often still experience uncontrolled debilitating symptoms. Transanal irrigation (TAI) has been described for the management of LARS symptoms that persist after conservative measures have been insufficient. The positive impact of this treatment on LARS and the number of bowel movements experienced by patients has been demonstrated in several, primarily European small studies. This multicenter, assessor-blinded, parallel-group randomized control trial (RCT) will assess the outcomes of an online, nurse-led, North American TAI program for the management of LARS. This RCT will recruit patients who have undergone a low anterior resection (LAR) with closure of any diverting stoma at least 6 months prior to entry into the trial with a LARS score of >20 at recruitment. Participants will be recruited from five academic hospitals with high volumes of rectal cancer care in Ontario and Quebec, and will be randomized using a computer-generated sequence in balanced blocks, stratified by hospital, to the intervention (TAI) or control (traditional care) arms. Participants in the intervention arm will be asked to perform TAI every 1-2 days for a six-month period. Teaching on the use of TAI will be given through virtual sessions with an experienced research nurse and supportive material (video and animated text) on a web-based application, eLARS. This is an established online application designed to provide quality health information for patients living with LARS created by our research group. Participants in the intervention arm of this study will be given access to a restricted transanal irrigation section on this application dedicated to this RCT with detailed written instructions and educational videos on the use of TAI. Participants in the control arm of the study will have access to the general eLARS application without the section on the transanal irrigation, and no specific change in their current management routine will be required. The required sample size for this RCT, accounting for attrition, is 99 patients. It is anticipated this patient sample can be accrued from the five interested sites within a year. The primary outcome of the study will be health-related quality of life (QoL) as measured by the European Organization for Research and Treatment of Cancer core Quality of Life questionnaire (EORTIC-QLQ-C30), with secondary outcomes including evaluation of bowel function by the LARS score, Wexner/Cleveland Clinic Fecal Incontinence Score, and bowel diary and satisfaction with TAI. Participant demographics, disease and treatment characteristics will be obtained via hospital chart review as time of recruitment. The TAI treatment effect on global QoL will be modeled using generalized estimating equations (GEE), accounting for within-subject correlations between responses at different time-points, and possible clustering of responses among participants from the same hospital. To our knowledge, this will be the first North American trial to assess TAI acceptance and impact on quality of life for patients living with LARS. Furthermore, this will be the largest RCT to date, and the first to use a virtual platform to deliver this service for rectal cancer survivors. This study aims to provide an additional feasible and acceptable treatment option for the management of LARS symptoms refractory to our currently limited treatment options.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Anterior Resection Syndrome, Rectal Cancer
Keywords
Transanal irrigations, Quality of Life

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Multicenter randomized controlled crossover trial
Masking
None (Open Label)
Masking Description
Allocation with be generated by a centralized computer generated randomized sequence to ensure allocation concealment. Data analyst will be blinding to treatment group but no other masking is feasible given the treatment
Allocation
Randomized
Enrollment
66 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transanal Irrigation
Arm Type
Experimental
Arm Description
This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm
Arm Title
Tradition care Control arm
Arm Type
No Intervention
Arm Description
This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.
Intervention Type
Procedure
Intervention Name(s)
Transanal Irrigation
Intervention Description
Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
Primary Outcome Measure Information:
Title
EORTC-QLQ-C30
Description
Quality of Life change with treatment. Scale scores are calculated by averaging items within scales and transforming average scores linearly. All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems. For more details, are available in the EORTC QLQ-C30 Scoring Manual (Fayers et al., 2001)
Time Frame
Monthly for the seven months of the trial
Secondary Outcome Measure Information:
Title
LARS Score
Description
Bowel function over the course of treatment. Scores range from 0 to 42 0-20: No LARS 21-29: Minor LARS 30-42: Major LARS
Time Frame
Monthly for the seven months of the trial
Title
Satisfaction Survey
Description
Satisfaction survey based on LARS Consensus Definition symptoms and consequences
Time Frame
Monthly for the seven months of the trial
Title
Bowel diaries
Description
Standardize measure of the number of bowel movement per day
Time Frame
Will be taken in first and last 2 week periods of each treatment groups

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Low anterior resection by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with (or without) creation of a diverting loop ileostomy for the treatment of rectal cancer, advanced adenoma or dysplasia And have had their ileostomy closed (if applicable) And completed treatment at least 6 months ago (including ileostomy closure) And LARS score > 20 points Exclusion Criteria: Inability to provide informed consent, including fluency in English or French language unable to access the internet, presence of an ostomy, no active or ongoing treatment anastomotic stricture, sinus or any other ongoing anastomotic complications.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah Sabboobeh
Phone
514-320-8222
Ext
25996
Email
sarah.sabboobeh@ladydavis.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Jessica Holland, MD
Ext
25996
Email
jessica.holland@mail.mcgill.ca
Facility Information:
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marylise Boutros, MD, MSc, FRCSC, FACS. FABCRS
Phone
514-340-8222
Ext
6821
Email
maryliseboutros@gmail.com
Facility Name
McGill University Health Centre
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Holland, MD
Email
jessica.holland@mail.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Sender Liberman

12. IPD Sharing Statement

Citations:
PubMed Identifier
32032141
Citation
Keane C, Fearnhead NS, Bordeianou LG, Christensen P, Basany EE, Laurberg S, Mellgren A, Messick C, Orangio GR, Verjee A, Wing K, Bissett I; LARS International Collaborative Group. International Consensus Definition of Low Anterior Resection Syndrome. Dis Colon Rectum. 2020 Mar;63(3):274-284. doi: 10.1097/DCR.0000000000001583.
Results Reference
background
PubMed Identifier
22935240
Citation
Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL. Anterior resection syndrome. Lancet Oncol. 2012 Sep;13(9):e403-8. doi: 10.1016/S1470-2045(12)70236-X.
Results Reference
background
PubMed Identifier
11858978
Citation
Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33. doi: 10.1016/s0959-8049(01)00448-8.
Results Reference
background
PubMed Identifier
33574345
Citation
Kim MJ, Park JW, Lee MA, Lim HK, Kwon YH, Ryoo SB, Park KJ, Jeong SY. Two dominant patterns of low anterior resection syndrome and their effects on patients' quality of life. Sci Rep. 2021 Feb 11;11(1):3538. doi: 10.1038/s41598-021-82149-9.
Results Reference
background
PubMed Identifier
26340884
Citation
Ekkarat P, Boonpipattanapong T, Tantiphlachiva K, Sangkhathat S. Factors determining low anterior resection syndrome after rectal cancer resection: A study in Thai patients. Asian J Surg. 2016 Oct;39(4):225-31. doi: 10.1016/j.asjsur.2015.07.003. Epub 2015 Sep 2.
Results Reference
background
PubMed Identifier
26953985
Citation
Battersby NJ, Juul T, Christensen P, Janjua AZ, Branagan G, Emmertsen KJ, Norton C, Hughes R, Laurberg S, Moran BJ; United Kingdom Low Anterior Resection Syndrome Study Group. Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer: A Multicenter Cross-Sectional Study. Dis Colon Rectum. 2016 Apr;59(4):270-80. doi: 10.1097/DCR.0000000000000552.
Results Reference
background
PubMed Identifier
27695976
Citation
Sturiale A, Martellucci J, Zurli L, Vaccaro C, Brusciano L, Limongelli P, Docimo L, Valeri A. Long-term functional follow-up after anterior rectal resection for cancer. Int J Colorectal Dis. 2017 Jan;32(1):83-88. doi: 10.1007/s00384-016-2659-6. Epub 2016 Sep 30.
Results Reference
background
PubMed Identifier
2724726
Citation
Iwama T, Imajo M, Yaegashi K, Mishima Y. Self washout method for defecational complaints following low anterior rectal resection. Jpn J Surg. 1989 Mar;19(2):251-3. doi: 10.1007/BF02471596.
Results Reference
background
PubMed Identifier
29226518
Citation
McCutchan GM, Hughes D, Davies Z, Torkington J, Morris C, Cornish JA; LARRIS Trial Management Group. Acceptability and benefit of rectal irrigation in patients with Low Anterior Resection Syndrome: a qualitative study. Colorectal Dis. 2017 Dec 11. doi: 10.1111/codi.13985. Online ahead of print.
Results Reference
background
PubMed Identifier
21689359
Citation
Rosen H, Robert-Yap J, Tentschert G, Lechner M, Roche B. Transanal irrigation improves quality of life in patients with low anterior resection syndrome. Colorectal Dis. 2011 Oct;13(10):e335-8. doi: 10.1111/j.1463-1318.2011.02692.x.
Results Reference
background
PubMed Identifier
19452159
Citation
Koch SM, Rietveld MP, Govaert B, van Gemert WG, Baeten CG. Retrograde colonic irrigation for faecal incontinence after low anterior resection. Int J Colorectal Dis. 2009 Sep;24(9):1019-22. doi: 10.1007/s00384-009-0719-x. Epub 2009 May 19.
Results Reference
background
PubMed Identifier
30083782
Citation
Martellucci J, Sturiale A, Bergamini C, Boni L, Cianchi F, Coratti A, Valeri A. Role of transanal irrigation in the treatment of anterior resection syndrome. Tech Coloproctol. 2018 Jul;22(7):519-527. doi: 10.1007/s10151-018-1829-7. Epub 2018 Aug 6.
Results Reference
background
PubMed Identifier
31585495
Citation
Enriquez-Navascues JM, Labaka-Arteaga I, Aguirre-Allende I, Artola-Etxeberria M, Saralegui-Ansorena Y, Elorza-Echaniz G, Borda-Arrizabalaga N, Placer-Galan C. A randomized trial comparing transanal irrigation and percutaneous tibial nerve stimulation in the management of low anterior resection syndrome. Colorectal Dis. 2020 Mar;22(3):303-309. doi: 10.1111/codi.14870. Epub 2019 Oct 21.
Results Reference
background
PubMed Identifier
15606588
Citation
Gosselink MP, Darby M, Zimmerman DD, Smits AA, van Kessel I, Hop WC, Briel JW, Schouten WR. Long-term follow-up of retrograde colonic irrigation for defaecation disturbances. Colorectal Dis. 2005 Jan;7(1):65-9. doi: 10.1111/j.1463-1318.2004.00696.x.
Results Reference
background
PubMed Identifier
31388638
Citation
Rosen HR, Kneist W, Furst A, Kramer G, Hebenstreit J, Schiemer JF. Randomized clinical trial of prophylactic transanal irrigation versus supportive therapy to prevent symptoms of low anterior resection syndrome after rectal resection. BJS Open. 2019 Mar 18;3(4):461-465. doi: 10.1002/bjs5.50160. eCollection 2019 Aug.
Results Reference
background
PubMed Identifier
33872283
Citation
Rodrigues BDS, Rodrigues FP, Buzatti KCLR, Campanati RG, Profeta da Luz MM, Gomes da Silva R, Lacerda-Filho A. Feasibility Study of Transanal Irrigation Using a Colostomy Irrigation System in Patients With Low Anterior Resection Syndrome. Dis Colon Rectum. 2022 Mar 1;65(3):413-420. doi: 10.1097/DCR.0000000000002005.
Results Reference
background

Learn more about this trial

Transanal Irrigation for the Management of LARS

We'll reach out to this number within 24 hrs